Skip to main content

CSL

CSL, Alentis Ink $1.55B Deal for Rare Kidney, Liver Drug

CSL, Alentis Ink $1.55B Deal for Rare Kidney, Liver Drug

Melbourne – October 4, 2026 -- CSL and Alentis Therapeutics have signed an exclusive global collaboration to develop and commercialize lixudebart, a potential first-in-class therapy targeting claudin-1 for rare kidney and liver diseases, with CSL paying Alentis US$355 million upfront and up to US$1.2 billion in commercial milestones.

CSL pays $355 million upfront, commits $1.2 billion in milestone payments

Under the agreement, CSL will fully fund the ongoing Phase 2 RENAL trial, the planned Phase 3 trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), and Phase 2 trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC). Once commercialized, global profits will be split 55 percent to CSL and 45 percent to Alentis.

CSL Seqirus Publishes Phase 3 Data on Triple-Technology Flu Vaccine in Lancet

Maidenhead, United Kingdom – September 16, 2026 -- CSL Seqirus has published pivotal Phase 3 results for its MF59-adjuvanted, cell-based, higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, reporting superiority over an adjuvanted egg-based comparator across all four influenza strains and age groups tested in a 7,699-participant trial.

Trial enrolled nearly 7,700 adults aged 50 and older across eight countries

The randomised, observer-blind study recruited participants in Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States, comparing aQIVc against an MF59-adjuvanted egg-based quadrivalent vaccine and a recombinant quadrivalent vaccine. The vaccine met its primary objectives, showing non-inferiority versus the recombinant comparator for three of four strains in the 50-plus group and four of four strains in those aged 65 and above.